Biotech Industry · us
Racing Against a 110-Minute Half-Life: GE HealthCare Plans to Acquire SOFIE for $945 Million
Whether PET imaging drugs reach hospitals on time affects access to scans. This acquisition will add 15 U.S. manufacturing sites and U.S. rights to FAPI-74, linking the supply network with the development of next-generation cancer imaging.
For positron emission tomography (PET) using fluorine-18-labeled drugs, time itself is a supply constraint: this radioactive isotope has a half-life of approximately 110 minutes, and every leg of the journey from manufacturing to hospital delivery consumes usable radioactivity. GE HealthCare now plans to acquire U.S. radiopharmaceutical manufacturer SOFIE Biosciences, bringing this supply chain racing against the clock under its ownership.
GE HealthCare announced on October 5 that it had reached an agreement with Trilantic North America to acquire SOFIE for $945 million in cash. SOFIE and Kirkland & Ellis, the law firm involved in the transaction, also confirmed the deal’s value and arrangements. The acquisition is expected to close in the first half of 2027, subject to regulatory approval and other closing conditions; SOFIE will then join GE HealthCare’s Pharmaceutical Diagnostics business.
At the heart of the transaction are SOFIE’s 15 U.S. contract manufacturing sites and 21 cyclotrons. For PET drugs with short half-lives, a production and distribution network close to healthcare facilities is an important requirement for bringing molecular imaging into routine clinical care. BioPharma Dive cited BTIG analyst Ryan Zimmerman’s view that additional manufacturing and distribution capacity could ease bottlenecks in radiopharmaceutical adoption; this is an assessment of the transaction’s potential benefits, rather than an improvement already achieved.
The two companies already have a supply partnership, with SOFIE manufacturing Flyrcado for GE HealthCare. SOFIE said it would continue producing existing products for current customers after closing, including products for other radiopharmaceutical companies; GE HealthCare will also continue working with other contract manufacturing partners. This means the network will continue serving the supply needs of multiple companies after the acquisition.
Beyond manufacturing capacity, the transaction will also bring U.S. rights to FAPI-74, a Phase 3 PET imaging drug candidate. The company hopes this fluorine-18-labeled fibroblast activation protein inhibitor tracer can be used to image multiple cancers; GE HealthCare already holds the rights outside the United States. However, the announcement did not provide Phase 3 trial results, and applications across multiple cancer types remain a development prospect, rather than approved uses or demonstrated diagnostic benefits.
GE HealthCare expects the acquisition to contribute positively to revenue growth, adjusted earnings before interest and taxes margin, and adjusted earnings per share in its first full year of SOFIE ownership. These remain the company’s financial projections, and the announcement did not quantify how much scan availability could increase or how much delivery times could shorten after closing. From an industry perspective, the transaction highlights a reality of radiopharmaceuticals: trials must establish the clinical value of new tracers, while getting them to patients on time requires a separate set of manufacturing and logistics capabilities.